Navigation Links
Daiichi Sankyo and Charleston Laboratories Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US
Date:8/6/2014

108 and will receive the right to co-promote this and other hydrocodone products in the United States.

Under the terms of the agreement, which is pending Hart-Scott-Rodino clearance, Charleston Laboratories will receive $200 million, split evenly between an upfront cash payment and a near-term milestone and up to an additional $450 million in milestone payments connected to the filing and approval of its novel fixed-dose hydrocodone products in the United States.  In addition, Charleston Laboratories will receive an escalating, tiered, double-digit share of the gross operating margin from the products.  

"We are proud to partner with Charleston Labs on this exciting and unique fixed-dose combination tablet, which will seek to simultaneously address severe pain and opioid-related nausea and vomiting to benefit patients," said Dr. Mahmoud Ghazzi, MD, PhD, Global Head of Development and Executive Vice President at Daiichi Sankyo Co., Ltd.

"CL-108 represents an opportunity at the intersection of innovation and patient need," said Ken Keller, President, U.S. Commercial of Daiichi Sankyo, Inc. "Daiichi Sankyo has proven success in the U.S. primary care arena, a key market for pain management, and we look forward to the potential of CL-108."

"From our inception, it has been our goal to identify an industry-leading partner that is patient-focused, with a shared appreciation for the importance of educating healthcare providers on the significant issue of Opioid-Induced Nausea and Vomiting," said Ryan Baker, Founder and Chief Operating Officer of Charleston Laboratories. "Daiichi Sankyo has successfully commercialized several medicines in the United States, and we feel they are the ideal strategic fit for Charleston's lead asset, CL-108."

"Charleston is e
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics
2. Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism
3. Daiichi Sankyos Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
4. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
5. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
6. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
7. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
8. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
9. CHPA Addresses Anti-Meth Policy at AP Lookahead Event Today in Charleston
10. CHPA to Address Anti-Meth Policy at AP Lookahead Event Today in Charleston
11. Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... LONDON , Sept. 16, 2014 ... wound closure market, Frost & Sullivan recognises Incisive ... Award for Customer Value Leadership. Incisive Surgical,s uniquely-designed, ... closure technology that eliminates the need for patients ... punctures and staple removal  that may result in ...
(Date:9/16/2014)... Sept. 16, 2014  Synereca Pharmaceutics, Inc. ... orally active drugs that restore or increase ... a $1.4 million convertible debt financing. Accele ... sciences accelerator Accele Biopharma, Inc., led the ... nationally recognized private not-for-profit corporation focused on ...
(Date:9/16/2014)... Sept. 16, 2014  Relmada Therapeutics, Inc., (OTCBB: RLMD), ... of chronic pain, announced today that it has entered ... (MSKCC) in a series of animal studies for levorphanol, ... extended release form of levorphanol.  Gavril Pasternak, MD, PhD, ... Dr. Pasternak said, "Levorphanol is a ...
Breaking Medicine Technology:Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 2Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 3Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 4Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 5Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3
... Study Success in Using Virus Enzyme to Treat Mouse ... Be Used to,Prevent Both Ear Infection and Pneumonia in ... -- Parents might one,day give their children a weekly ... them from getting a severe middle ear,infection, based on ...
... the Drug Improves Memory, SARASOTA, Fla., March 22, ... it has received positive,preliminary results in its major ... application for the treatment of Alzheimer's,disease. The clinical ... first human clinical study conducted by a,Florida-based research ...
Cached Medicine Technology:Viral Enzyme Recruited in Fight Against Ear Infection 2Viral Enzyme Recruited in Fight Against Ear Infection 3Sarasota's Roskamp Institute Announces Positive Safety Data in,Human Clinical Study for Alzheimer's Disease 2
(Date:9/16/2014)... (PRWEB) September 16, 2014 SAMHSA, the federal ... mission a reduction of the impact of substance abuse and ... on the SAMHSA website in September is National Recovery Month, ... honor the gains made by those individuals in recovery. ... to addiction treatment in an effort to help those with ...
(Date:9/16/2014)... REDWOOD CITY, CALIF. (PRWEB) September 16, 2014 ... contact center and customer service solutions, announced today ... Group Excellence in Learning Award for the creation ... for independent contractor agents. Brandon Hall Group honors ... strategies, modalities, processes, systems and tools that have ...
(Date:9/16/2014)... Former Major League Baseball relief pitcher ... heart transplantation surgery at Allegheny General Hospital (AGH) on ... of his 16-year baseball career with the Pittsburgh Pirates ... Root Sports Pittsburgh, was discharged home on Friday, September ... surgical director of AGH’s heart transplant program. , “Mr. ...
(Date:9/16/2014)... inoperable, early-stage lung cancer who receive stereotactic body ... of 40 percent, according to research presented today ... 56th Annual Meeting. Such a positive survival rate ... in poor tumor control for patients with inoperable ... RTOG 0236, originally published in 2010 , and ...
(Date:9/16/2014)... to be on the heavy side. Researchers at the ... seven in every ten obese adults underestimate how much ... much less often. Mothers of overweight or obese children ... misjudge their obese mothers, size, says lead author Tracy ... in the Journal of General Internal Medicine , ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Booklet Offers Tips During Recovery Month 2Health News:Narconon Arrowhead Booklet Offers Tips During Recovery Month 3Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 2Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 3Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 4Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 2Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 3Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 2Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 3Health News:Poor body size judgement can lead to increased tolerance of obesity 2
... Your Medicines and You, Event Provides Free Pharmacist Reviews ... Mistakes, CHICAGO, Oct. 31 The following is ... one of the leading causes of death for,individuals over ... are teaming,up this Thursday to help people better manage ...
... Oct. 31 Varian, Inc.,(Nasdaq: VARI ) ... TOP-DNA and TOP-RNA, for the purification of,synthetic oligonucleotides ... used by life science researchers to,study the functions ... to work,properly, salts and incomplete products need to ...
... 11:01 AM October 31, 2007, WASHINGTON, ... of AARP told lawmakers what American families,already know ... our country is,the skyrocketing costs of health care., ... CEO Bill Novelli testified at a Senate Budget ...
... Another Scientific Review ... ... DENVER, Oct. 31 "The WCRF/AICR recommendations about,red meat and cancer are unsubstantiated ... red meat in a healthy,diet that far outweigh anything we,ve seen today. "There ...
... Open-Bore, Design to Bring High-Resolution MR Imaging to More Patients ... ... MALVERN, Pa., Oct. 31 Combining 3 Tesla strength and,sensitivity with a ... a 3 Tesla (T) MRI system with a 70 cm open bore ...
... to ways to treat injury, stroke and even Alzheimer,s, experts ... new U.S. study involving mice suggests the brain,s own stem ... injury. , These neural stem cells work by protecting existing ... team at the University of California, Irvine, were able to ...
Cached Medicine News:Health News:Varian, Inc. Offers New Products for the Rapid Purification of Synthetic Oligonucleotides. 2Health News:AARP CEO Bill Novelli Tells Lawmakers: Controlling Health Care Costs Key to Budget Reform 2Health News:NCBA Statement on 2007 WCRF/AICR Second Expert Report on Food, Nutrition and Physical Activity and the Prevention of Cancer: 2Health News:3 Tesla + 70 cm + Tim = The Most Exciting Equation in MRI 2Health News:3 Tesla + 70 cm + Tim = The Most Exciting Equation in MRI 3Health News:3 Tesla + 70 cm + Tim = The Most Exciting Equation in MRI 4Health News:Stem Cells Restore Memory in Mice 2Health News:Stem Cells Restore Memory in Mice 3
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
The Erythrocyte Sedimentation Rate (ESR) can be used as a nonspecific search technique in case of suspicion of inflammatory reactions as well as for judgement of their development. VACUETTE ESR tubes...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Glucose tubes contain an anti-coagulant and a stabiliser. The tubes are ideal for glucose and lactate determinations....
Medicine Products: